Trial Profile

Dalbavancin vs linezolid for treatment of acute bacterial infections of the skin.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary) ; Linezolid
Indications Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
Focus Registrational; Therapeutic Use
Sponsors Vicuron Pharmaceuticals

Most Recent Events

05 Jun 2017 Results of retrospective analysis presented at the ASM Microbe 2017
25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data from four phase III studies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
30 Oct 2016 Pooled results of this and other 3 trial (DUR001-301, DUR001-302 and DUR001-303) presented at the IDWeek 2016

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com